Dermatitis - contact
Also known as: Dandruff, Seborrhea, Seborrheic, Dermatitis
Methodology & AI Transparency ⓘ
Dermatitis - contact Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Dermatitis - contact (also termed Dandruff or Seborrhea) (ICD-10-CM L25.9), Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols prioritize contact/systemic trigger review [Dermatitis - contact L25.9] paired with baseline and interval 25-Hydroxy Vitamin D in Dermatitis - contact (L25.9: & hs-CRP) assessment.
- 2 Real-world patient consensus: Synonyms for Dermatitis - contact (L25.9): Dandruff, Seborrhea, Seborrheic (Skin & Dermatology).
- 3 Typical cash cost range: Primary evaluation for Dermatitis - contact incorporates contact/systemic trigger review [Dermatitis - contact L25.9] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Dermatitis - contact: 25-Hydroxy Vitamin D in Dermatitis - contact (L25.9: & hs-CRP) (25(OH)D 40–65 ng/mL (L25.9)) and Affected Body Surface in Dermatitis - contact (L25.9: Area (BSA /).
Ask our AI Specialists anything about Dermatitis - contact
What Is Dermatitis - contact?
For patients presenting with Dermatitis - contact (also termed Dandruff or Seborrhea) (ICD-10-CM L25.9), Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols prioritize contact/systemic trigger review [Dermatitis - contact L25.9] paired with baseline and interval 25-Hydroxy Vitamin D in Dermatitis - contact (L25.9: & hs-CRP) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in skin & dermatology, Dermatitis - contact (L25.9) involves keratinocyte hyperproliferation [Dermatitis - contact L25.9]. progression correlates with shifts in 25-Hydroxy Vitamin D in Dermatitis - contact (L25.9: & hs-CRP) (25(OH)D 40–65 ng/mL (L25.9)).
Common Symptoms & Clinical Signs
- • Presentation of Dermatitis - contact (L25.9): persistent erythematous plaques, in Dermatitis - contact (L25.9: scaly patches, pruritic)
- • Secondary Dermatitis - contact clinical sign: compromised epidermal barrier in Dermatitis - contact (L25.9: with dryness, fissuring,)
- • Symptom flares in Dermatitis - contact correlating with 25-Hydroxy Vitamin D in Dermatitis - contact (L25.9: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L25.9)
- • Functional skin & dermatology impact requiring contact/systemic trigger review [Dermatitis - contact L25.9] evaluation (L25.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Dermatitis - contact Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L25.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Dermatitis - contact (L25.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (L25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Dermatitis - contact (L25.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Dermatitis - contact (L25.9: ALT (if systemic) | Within baseline reference limits (L25.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Dermatitis - contact
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dapsone Aczone • RxCUI 197557 | Sulfone | 90% | $0.5828 | $ 11.04 /mo |
| Nickel Sulfate, Potassium Bromide, and Fumaric Acid Psorizide Forte • RxCUI RXN-61480255-1781 | FDA Prescription Therapeutic Agent | 76% | $1.7700 | $ 80.19 /mo |
| Aczone (Dapsone) Aczone • RxCUI 197557-B16110526 | Sulfone | 90% | $1.0480 | $ 11.04 /mo |
| Pureskin Seborrheic Dermatitis and Psoriasis Cream (Seborrheic Dermatitis Psoriasis Cream) Pureskin Seborrheic Dermatitis and Psoriasis Cream • RxCUI 317152 | Over-the-Counter Clinical Monograph | 85% | $2.9400 | $ 220.18 /mo |
| Dapsone 25 Mg (Dapsone Tablets) Dapsone 25 Mg • RxCUI RXN-B83098102 | Sulfone | 92% | $1.0480 | $ 83.95 /mo |
| Oral Ivy Liquid (Toxicodendron Pubescens Leaf) Oral Ivy Liquid • RxCUI RXN-B684662015 | Over-the-Counter Clinical Monograph | 77% | $1.5700 | $ 121.54 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dermatitis - contact)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe: What a 2,856-Participant Study Found Abrocitinib, with proper patient and dose selection, has a manageable tolerability and longer-term safety profile appropriate for long-term use in patients with moderate-to-severe AD. American journal of clinical dermatology • 2021-09-15 • Phase III Randomized Trial | N = 2,856 | 96/100 | PMID 34406619 ↗ |
| New Insights on Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults: What a 2,444-Participant Study Found In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD outcomes vs. The Journal of dermatological treatment • 2022-02-15 • Phase III Randomized Trial | N = 2,444 | 96/100 | PMID 32347763 ↗ |
| New Insights on Immunogenicity of dupilumab in adult and children patients with: What a 2,992-Participant Study Found In patients with AD, ADAs and NAbs had minimal impact on dupilumab concentration, efficacy, and safety, except for high-titer ADAs in a small number of patients. Frontiers in immunology • 2024-01-15 • Phase III Randomized Trial | N = 2,992 | 96/100 | PMID 39588375 ↗ |
| New Insights on Upadacitinib for moderate-to-severe eczema: Stratified analysis from three: What a 2,584-Participant Study Found Upadacitinib had consistently high skin clearance rates and itch efficacy across subgroups of patients with moderate-to-severe AD through Week 16. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | N = 2,584 | 96/100 | PMID 37247226 ↗ |
| New Insights on Bilateral Association Between eczema® and hair loss: What a 233,448-Participant Study Found Based on 7 studies, there was a significant association between AD and AA when AA was the exposure factor [odds ratio, OR, = 4.537 (95% CI: 2.409-8.544)]; based on 10 studies, there was also a significant association between... Dermatitis : contact, atopic, occupational, drug • 2024-01-15 • Meta-Analysis | N = 233,448 | 94/100 | PMID 37471232 ↗ |
Dermatitis - contact Patient Community & “People Like Me” Threads
Filter Dermatitis - contact community threads and patient logs by age, biological sex, dosage, and treatment duration.